Symbols / VALN Stock $5.53 +0.73% Valneva SE

Healthcare • Biotechnology • France • NMS
VALN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Thomas Lingelbach
Exch · Country NMS · France
Market Cap 480.43M
Enterprise Value 1.06B
Income -115.19M
Sales 174.66M
FCF (ttm) -49.67M
Book/sh 1.43
Cash/sh 0.63
Employees 674
Insider 10d —
IPO May 05, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 6.83
PEG —
P/S 2.75
P/B 3.87
P/C —
EV/EBITDA -16.33
EV/Sales 6.05
Quick Ratio 1.47
Current Ratio 2.38
Debt/Eq 195.21
LT Debt/Eq —
EPS (ttm) -1.59
EPS next Y 0.81
EPS Growth —
Revenue Growth -9.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-18
Earnings (prior) 2026-03-18
ROA -11.35%
ROE -80.16%
ROIC —
Gross Margin -10.18%
Oper. Margin -58.05%
Profit Margin -65.95%
Shs Outstand 86.88M
Shs Float 140.69M
Insider Own 0.00%
Instit Own 6.00%
Short Float 0.17%
Short Ratio 0.95
Short Interest 145.60K
52W High 12.25
vs 52W High -54.86%
52W Low 5.15
vs 52W Low 7.38%
Beta 1.53
Impl. Vol. —
Rel Volume 0.33
Avg Volume 86.30K
Volume 28.22K
Target (mean) $12.22
Tgt Median $13.00
Tgt Low $4.90
Tgt High $18.00
# Analysts 4
Recom Buy
Prev Close $5.49
Price $5.53
Change 0.73%
About

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.23
Mean price target
2. Current target
$5.53
Latest analyst target
3. DCF / Fair value
$-10.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.53
Low
$4.90
High
$18.00
Mean
$12.23

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-08 main Guggenheim Buy → Buy $13
2025-08-25 reit HC Wainwright & Co. Buy → Buy $18
2025-05-08 main Guggenheim Buy → Buy $14
2025-04-15 reit HC Wainwright & Co. Buy → Buy $17
2025-04-09 reit HC Wainwright & Co. Buy → Buy $17
2025-04-02 reit HC Wainwright & Co. Buy → Buy $17
2025-03-31 reit HC Wainwright & Co. Buy → Buy $17
2025-03-24 reit HC Wainwright & Co. Buy → Buy $17
2025-03-24 main Guggenheim Buy → Buy $15
2025-03-21 reit HC Wainwright & Co. Buy → Buy $17
2025-02-28 reit HC Wainwright & Co. Buy → Buy $17
2025-02-19 main HC Wainwright & Co. Buy → Buy $17
2025-02-05 reit HC Wainwright & Co. Buy → Buy $18
2025-01-31 reit HC Wainwright & Co. Buy → Buy $18
2025-01-23 main HC Wainwright & Co. Buy → Buy $18
2025-01-22 main HC Wainwright & Co. Buy → Buy $18
2024-10-11 main HC Wainwright & Co. Buy → Buy $20
2024-09-25 main HC Wainwright & Co. Buy → Buy $23
2024-09-03 reit HC Wainwright & Co. Buy → Buy $26
2024-08-14 reit HC Wainwright & Co. Buy → Buy $26
News
RSS: Latest VALN news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
174.66
+3.00%
169.58
+10.32%
153.71
-57.46%
361.30
Operating Revenue
174.66
+3.00%
169.58
+10.32%
153.71
-57.46%
361.30
Cost Of Revenue
107.14
+8.73%
98.54
-2.32%
100.88
-68.91%
324.44
Reconciled Cost Of Revenue
107.14
+8.73%
98.54
-2.32%
100.88
-68.91%
324.44
Gross Profit
67.52
-4.96%
71.04
+34.45%
52.84
+43.34%
36.86
Operating Expense
149.15
+0.23%
148.81
+10.27%
134.95
-10.22%
150.31
Research And Development
85.30
+15.05%
74.14
+23.79%
59.89
-42.92%
104.92
Selling General And Administration
74.68
-21.48%
95.11
-1.50%
96.55
+67.68%
57.58
Selling And Marketing Expense
37.36
-28.65%
52.36
+7.39%
48.75
+107.38%
23.51
General And Administrative Expense
37.32
-12.70%
42.75
-10.56%
47.80
+40.28%
34.07
Other Gand A
37.32
-12.70%
42.75
-10.56%
47.80
+40.28%
34.07
Other Operating Expenses
-11.20
+46.10%
-20.79
+5.39%
-21.97
-80.10%
-12.20
Total Expenses
256.29
+3.62%
247.35
+4.89%
235.82
-50.33%
474.75
Operating Income
-81.63
-4.97%
-77.77
+5.29%
-82.11
+27.62%
-113.44
Total Operating Income As Reported
-82.06
-715.60%
13.33
+116.24%
-82.09
+27.64%
-113.44
EBITDA
-50.47
-257.31%
32.08
+155.59%
-57.72
+44.88%
-104.72
Normalized EBITDA
-57.24
-263.48%
35.01
+155.29%
-63.32
+31.28%
-92.14
Reconciled Depreciation
21.75
+11.05%
19.59
+11.39%
17.58
-16.41%
21.04
EBIT
-72.22
-677.86%
12.50
+116.60%
-75.30
+40.12%
-125.76
Total Unusual Items
6.76
+331.12%
-2.93
-152.29%
5.60
+144.47%
-12.59
Total Unusual Items Excluding Goodwill
6.76
+331.12%
-2.93
-152.29%
5.60
+144.47%
-12.59
Special Income Charges
-0.43
-262.03%
0.27
+1008.33%
0.02
+134.29%
-0.07
Other Special Charges
-0.00
+99.86%
-0.71
-1480.00%
-0.04
-240.63%
0.03
Net Income
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Pretax Income
-114.12
-893.55%
-11.49
+88.35%
-98.63
+31.89%
-144.81
Net Non Operating Interest Income Expense
-39.25
-81.55%
-21.62
+2.23%
-22.11
-17.67%
-18.79
Interest Expense Non Operating
41.90
+74.69%
23.98
+2.83%
23.32
+22.42%
19.05
Net Interest Income
-39.25
-81.55%
-21.62
+2.23%
-22.11
-17.67%
-18.79
Interest Expense
41.90
+74.69%
23.98
+2.83%
23.32
+22.42%
19.05
Interest Income Non Operating
1.80
-23.67%
2.36
+95.21%
1.21
+365.38%
0.26
Interest Income
1.80
-23.67%
2.36
+95.21%
1.21
+365.38%
0.26
Other Income Expense
6.76
-92.30%
87.91
+1470.31%
5.60
+144.51%
-12.58
Other Non Operating Income Expenses
—
90.83
—
—
Gain On Sale Of Security
7.20
+325.37%
-3.19
-157.28%
5.57
+144.28%
-12.59
Tax Provision
1.07
+41.00%
0.76
-72.82%
2.80
+282.29%
-1.54
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+2256.93%
0.00
Tax Effect Of Unusual Items
1.69
+331.12%
-0.73
-152.29%
1.40
+1148.27%
-0.13
Net Income Including Noncontrolling Interests
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Net Income From Continuing Operation Net Minority Interest
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Net Income From Continuing And Discontinued Operation
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Net Income Continuous Operations
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Normalized Income
-120.27
-1096.47%
-10.05
+90.48%
-105.63
+19.26%
-130.83
Net Income Common Stockholders
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Diluted EPS
—
-0.16
+89.04%
-1.46
+41.13%
-2.48
Basic EPS
—
-0.16
+89.04%
-1.46
+41.13%
-2.48
Basic Average Shares
—
72.85
+4.87%
69.47
+20.25%
57.77
Diluted Average Shares
—
72.85
+4.87%
69.47
+20.25%
57.77
Diluted NI Availto Com Stockholders
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Earnings From Equity Interest
—
0.00
0.00
-100.00%
0.01
Gain On Sale Of PPE
-0.43
+2.92%
-0.45
-2019.05%
-0.02
+44.74%
-0.04
Other Taxes
0.37
+7.80%
0.35
-27.16%
0.47
+118.89%
0.22
Total Other Finance Cost
-0.84
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
398.84
-20.24%
500.03
+8.69%
460.06
-25.96%
621.34
Current Assets
222.54
-25.57%
299.01
+13.77%
262.82
-38.11%
424.66
Cash Cash Equivalents And Short Term Investments
109.65
-34.84%
168.27
+33.46%
126.08
-56.00%
286.53
Cash And Cash Equivalents
109.65
-34.84%
168.27
+33.46%
126.08
-56.00%
286.53
Cash Equivalents
—
0.00
+100.00%
-0.00
+0.00%
-0.00
Cash Financial
109.65
-34.84%
168.27
+33.46%
126.08
-56.00%
286.53
Receivables
27.81
-21.00%
35.20
-15.46%
41.65
+74.15%
23.91
Accounts Receivable
27.73
-21.06%
35.13
-15.64%
41.65
+74.15%
23.91
Gross Accounts Receivable
27.79
-21.02%
35.18
-15.66%
41.71
+73.83%
24.00
Allowance For Doubtful Accounts Receivable
-0.05
+0.00%
-0.05
+24.64%
-0.07
+17.86%
-0.08
Other Receivables
0.08
+6.67%
0.07
—
—
Inventory
50.23
-6.39%
53.66
+20.68%
44.47
+26.67%
35.10
Raw Materials
25.85
-7.97%
28.09
-20.61%
35.38
-59.08%
86.45
Work In Process
48.09
+30.58%
36.83
-3.31%
38.09
-66.65%
114.22
Finished Goods
20.75
-14.45%
24.25
+46.17%
16.59
+8.45%
15.30
Restricted Cash
—
—
0.00
-100.00%
2.90
Assets Held For Sale Current
—
—
0.00
-100.00%
2.13
Other Current Assets
34.85
-16.78%
41.87
-17.30%
50.63
-31.65%
74.08
Total Non Current Assets
176.30
-12.30%
201.02
+1.92%
197.24
+0.28%
196.69
Net PPE
138.03
-12.70%
158.12
+0.97%
156.59
+1.66%
154.04
Gross PPE
247.92
+56.80%
158.12
+0.97%
156.59
+1.66%
154.04
Accumulated Depreciation
-109.89
-15.47%
-95.17
—
-67.15
Properties
0.00
0.00
0.00
0.00
Land And Improvements
147.41
-2.40%
151.03
—
96.53
Machinery Furniture Equipment
5.04
-0.38%
5.05
—
5.39
Construction In Progress
1.03
-70.67%
3.52
—
1.58
Other Properties
76.25
-45.21%
139.18
+2.00%
136.45
+21.10%
112.67
Leases
18.19
-3.90%
18.93
-6.00%
20.14
-51.31%
41.37
Goodwill And Other Intangible Assets
22.35
-11.52%
25.26
-1.20%
25.57
-10.95%
28.71
Other Intangible Assets
22.35
-11.52%
25.26
-1.20%
25.57
-10.95%
28.71
Investments And Advances
—
—
—
0.00
Long Term Equity Investment
—
—
—
0.00
Non Current Deferred Assets
8.33
-13.32%
9.61
+45.71%
6.59
+16.94%
5.64
Non Current Deferred Taxes Assets
8.33
-13.32%
9.61
+45.71%
6.59
+16.94%
5.64
Other Non Current Assets
7.59
-5.60%
8.04
-5.28%
8.49
+2.29%
8.30
Total Liabilities Net Minority Interest
292.67
-8.19%
318.78
-3.93%
331.81
-17.37%
401.55
Current Liabilities
93.33
-18.54%
114.58
-27.88%
158.86
-42.73%
277.39
Payables And Accrued Expenses
31.45
-27.88%
43.61
-13.34%
50.33
+7.12%
46.98
Payables
15.99
-22.88%
20.73
-12.12%
23.59
+17.97%
20.00
Accounts Payable
9.07
-28.21%
12.64
-28.04%
17.56
+21.09%
14.51
Other Payable
—
—
—
4.96
Current Accrued Expenses
15.47
-32.41%
22.88
-14.42%
26.74
-0.92%
26.99
Employee Benefits
—
—
—
1.32
Pensionand Other Post Retirement Benefit Plans Current
12.64
-3.55%
13.11
+21.19%
10.81
+0.34%
10.78
Total Tax Payable
6.91
-14.56%
8.09
+34.28%
6.03
+9.72%
5.49
Income Tax Payable
0.00
-99.94%
1.74
+175.63%
0.63
+18.80%
0.53
Current Debt And Capital Lease Obligation
20.64
-11.63%
23.36
-50.25%
46.96
+26.94%
36.99
Current Debt
17.91
-14.13%
20.85
-52.69%
44.08
+280.65%
11.58
Other Current Borrowings
17.91
-14.13%
20.85
-52.69%
44.08
+280.65%
11.58
Current Capital Lease Obligation
2.74
+9.21%
2.51
-12.89%
2.88
-88.67%
25.41
Current Deferred Liabilities
0.43
-85.65%
3.01
-47.17%
5.70
-39.46%
9.41
Current Deferred Revenue
0.43
-85.65%
3.01
-47.17%
5.70
-39.46%
9.41
Other Current Liabilities
5.69
+10.42%
5.15
+770.27%
0.59
-89.28%
5.52
Total Non Current Liabilities Net Minority Interest
199.33
-2.38%
204.20
+18.07%
172.95
+39.30%
124.15
Long Term Debt And Capital Lease Obligation
186.60
-3.29%
192.95
+19.21%
161.86
+40.27%
115.39
Long Term Debt
161.26
-3.16%
166.52
+25.42%
132.77
+52.21%
87.23
Long Term Capital Lease Obligation
25.34
-4.12%
26.43
-9.14%
29.09
+3.29%
28.16
Long Term Provisions
8.08
+14.76%
7.04
-4.61%
7.38
-7.27%
7.96
Non Current Deferred Liabilities
4.41
+5.93%
4.16
+14.40%
3.64
+424.21%
0.69
Non Current Deferred Revenue
—
—
—
0.00
Non Current Deferred Taxes Liabilities
4.41
+5.93%
4.16
+14.40%
3.64
+424.21%
0.69
Other Non Current Liabilities
0.24
+410.42%
0.05
-39.24%
0.08
-31.30%
0.12
Stockholders Equity
106.17
-41.43%
181.25
+41.33%
128.25
-41.65%
219.80
Common Stock Equity
106.17
-41.43%
181.25
+41.33%
128.25
-41.65%
219.80
Capital Stock
26.03
+6.78%
24.38
+16.99%
20.84
+0.40%
20.75
Common Stock
26.03
+6.78%
24.38
+16.99%
20.84
+0.40%
20.75
Share Issued
173.54
+6.78%
162.52
+17.00%
138.91
+0.30%
138.49
Ordinary Shares Number
173.42
+6.78%
162.40
+17.01%
138.79
+0.30%
138.37
Treasury Shares Number
0.12
+0.00%
0.12
+0.00%
0.12
+0.00%
0.12
Additional Paid In Capital
675.94
+4.38%
647.60
+9.02%
594.00
-0.01%
594.04
Retained Earnings
-679.12
-20.43%
-563.93
-2.22%
-551.68
-22.53%
-450.25
Gains Losses Not Affecting Retained Earnings
40.74
+1.46%
40.15
-3.09%
41.43
+8.28%
38.26
Treasury Stock
0.65
+0.00%
0.65
+0.00%
0.65
+0.00%
0.65
Other Equity Adjustments
40.74
+1.46%
40.15
-3.09%
41.43
+8.28%
38.26
Total Equity Gross Minority Interest
106.17
-41.43%
181.25
+41.33%
128.25
-41.65%
219.80
Total Capitalization
267.43
-23.10%
347.77
+33.24%
261.01
-14.99%
307.02
Working Capital
129.21
-29.94%
184.43
+77.41%
103.96
-29.41%
147.27
Invested Capital
285.33
-22.60%
368.63
+20.82%
305.09
-4.24%
318.60
Total Debt
207.25
-4.19%
216.31
+3.59%
208.82
+37.04%
152.38
Net Debt
69.52
+263.90%
19.10
-62.37%
50.77
—
Capital Lease Obligations
28.08
-2.96%
28.94
-9.47%
31.97
-40.33%
53.57
Net Tangible Assets
83.82
-46.27%
155.99
+51.92%
102.68
-46.27%
191.09
Tangible Book Value
83.82
-46.27%
155.99
+51.92%
102.68
-46.27%
191.09
Current Provisions
22.47
-14.67%
26.34
-40.78%
44.47
-73.48%
167.71
Inventories Adjustments Allowances
-44.46
-25.21%
-35.51
+22.13%
-45.60
+74.79%
-180.87
Investmentsin Associatesat Cost
—
—
—
0.00
Other Equity Interest
43.22
+28.27%
33.70
+38.66%
24.30
+37.81%
17.64
Other Inventories
—
—
—
-0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-52.89
+21.31%
-67.22
+66.85%
-202.74
+17.36%
-245.34
Cash Flow From Continuing Operating Activities
-52.90
+21.31%
-67.22
+66.85%
-202.75
+17.36%
-245.34
Net Income From Continuing Operations
-115.19
-840.57%
-12.25
+87.93%
-101.43
+29.21%
-143.28
Depreciation Amortization Depletion
21.75
+11.05%
19.59
+11.39%
17.58
-16.41%
21.04
Depreciation And Amortization
21.75
+11.05%
19.59
+11.39%
17.58
-16.41%
21.04
Other Non Cash Items
30.40
+35.00%
22.52
+5.66%
21.31
-35.19%
32.88
Pension And Employee Benefit Expense
1.41
+188.33%
-1.59
+3.92%
-1.66
+92.77%
-22.93
Stock Based Compensation
9.53
+19.54%
7.97
+56.04%
5.11
+159.05%
-8.66
Asset Impairment Charge
0.90
0.00
+100.00%
-0.73
-103.14%
23.25
Deferred Tax
1.07
+41.00%
0.76
-72.82%
2.80
+282.29%
-1.54
Deferred Income Tax
1.07
+41.00%
0.76
-72.82%
2.80
+282.29%
-1.54
Operating Gains Losses
1.00
+101.08%
-92.69
-8396.15%
-1.09
+95.24%
-22.90
Gain Loss On Investment Securities
-0.84
—
—
—
Gain Loss On Sale Of PPE
0.43
+262.41%
-0.27
-2116.67%
-0.01
-131.58%
0.04
Change In Working Capital
-0.15
+98.72%
-11.57
+92.02%
-145.06
+0.63%
-145.98
Change In Receivables
13.33
-15.16%
15.71
+650.16%
-2.85
-123.02%
12.40
Change In Inventory
1.03
+115.17%
-6.80
+25.77%
-9.16
-110.88%
84.22
Change In Payables And Accrued Expense
-4.46
-34.15%
-3.32
+80.91%
-17.40
-23.80%
-14.05
Change In Payable
-4.46
-34.15%
-3.32
+80.91%
-17.40
-23.80%
-14.05
Change In Other Working Capital
-2.60
+6.91%
-2.79
+19.53%
-3.47
+97.10%
-119.84
Change In Other Current Assets
0.45
-0.67%
0.45
+333.85%
-0.19
-101.75%
10.98
Change In Other Current Liabilities
-7.90
+46.69%
-14.81
+86.77%
-111.98
+6.44%
-119.69
Investing Cash Flow
-1.71
-102.22%
76.92
+473.65%
-20.59
+29.15%
-29.05
Cash Flow From Continuing Investing Activities
-1.71
-102.22%
76.92
+473.67%
-20.58
+29.15%
-29.05
Net PPE Purchase And Sale
-4.29
+68.67%
-13.70
+2.97%
-14.12
+51.71%
-29.24
Purchase Of PPE
-4.42
+68.12%
-13.87
+2.57%
-14.23
+51.34%
-29.25
Sale Of PPE
0.13
-22.42%
0.17
+48.65%
0.11
+1287.50%
0.01
Capital Expenditure
-4.48
+72.75%
-16.44
-14.90%
-14.31
+51.19%
-29.32
Net Investment Purchase And Sale
0.84
0.00
0.00
—
Sale Of Investment
0.84
0.00
0.00
—
Net Business Purchase And Sale
0.00
0.00
+100.00%
-10.95
0.00
Purchase Of Business
0.00
0.00
+100.00%
-10.95
0.00
Net Intangibles Purchase And Sale
-0.06
+97.63%
-2.58
-3083.95%
-0.08
-6.58%
-0.08
Purchase Of Intangibles
-0.06
+97.63%
-2.58
-3083.95%
-0.08
-6.58%
-0.08
Net Other Investing Changes
—
90.83
+2605.78%
3.36
—
Financing Cash Flow
-0.62
-102.02%
30.68
-51.36%
63.08
-70.68%
215.12
Cash Flow From Continuing Financing Activities
-0.62
-102.03%
30.68
-51.36%
63.08
-70.68%
215.12
Net Issuance Payments Of Debt
0.06
+100.94%
-6.49
-108.55%
75.89
+120.03%
34.49
Issuance Of Debt
174.40
—
81.11
+106.23%
39.33
Repayment Of Debt
-174.34
-2587.53%
-6.49
-24.18%
-5.22
-7.91%
-4.84
Long Term Debt Issuance
174.40
—
81.11
+106.23%
39.33
Long Term Debt Payments
-174.34
-2587.53%
-6.49
-24.18%
-5.22
-7.91%
-4.84
Net Long Term Debt Issuance
0.06
+100.94%
-6.49
-108.55%
75.89
+120.03%
34.49
Net Common Stock Issuance
30.00
-47.49%
57.14
+23907.92%
-0.24
-100.13%
189.84
Common Stock Payments
—
—
-0.24
—
Cash Dividends Paid
0.00
0.00
0.00
0.00
Repurchase Of Capital Stock
—
—
-0.24
—
Net Other Financing Charges
0.00
+200.00%
-0.00
-200.00%
0.00
—
Changes In Cash
-55.22
-236.76%
40.38
+125.20%
-160.25
-170.31%
-59.28
Effect Of Exchange Rate Changes
-3.40
-287.58%
1.81
+987.75%
-0.20
+75.36%
-0.83
Beginning Cash Position
168.27
+33.46%
126.08
-56.00%
286.53
-17.34%
346.64
End Cash Position
109.65
-34.84%
168.27
+33.46%
126.08
-56.00%
286.53
Free Cash Flow
-57.38
+31.42%
-83.66
+61.46%
-217.06
+20.97%
-274.67
Common Stock Issuance
—
—
0.00
-100.00%
189.84
Dividend Received CFO
—
0.00
0.00
0.00
Earnings Losses From Equity Investments
—
0.00
0.00
+100.00%
-0.01
Interest Paid CFF
-30.69
-53.67%
-19.97
-58.90%
-12.57
-36.43%
-9.21
Interest Received CFI
1.80
-23.67%
2.36
+95.21%
1.21
+365.38%
0.26
Issuance Of Capital Stock
—
—
0.00
-100.00%
189.84
Other Cash Adjustment Outside Changein Cash
—
—
—
2.90
Sale Of Intangibles
—
—
—
0.00
Taxes Refund Paid
-2.20
-42.59%
-1.54
-25.00%
-1.24
-702.60%
-0.15
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category